Myositis-specific and myositis-associated antibodies in a series of eighty-eight mediterranean patients with idiopathic inflammatory myopathy

Arthritis Care and Research

Volumn 55, Issue 5, 2006, Pages 791-798

  Selva O'Callaghan, Albert ^a,b   Labrador Horrillo, Moisés ^a   Solans Laque, Roser ^a   Simeon Aznar, Carmen Pilar ^a   Martínez Gómez, Xavier ^a   Vilardell Tarrés, Miquel ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b NONE   (Spain)

Author keywords

Antisynthetase antibodies; Autoantibodies; Dermatomyositis; Polymyositis

Indexed keywords

AUTOANTIBODY; HLA DR3 ANTIGEN; KU ANTIBODY; MI 2 ANTIBODY; MYOSITIS ASSOCIATED ANTIBODY; MYOSITIS SPECIFIC ANTIBODY; OLIGONUCLEOTIDE; PROTEIN; RIBONUCLEOPROTEIN ANTIBODY; RNA; RO ANTIBODY; SYNTHETASE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTHRITIS; ARTICLE; CORRELATION ANALYSIS; DISEASE COURSE; DYSPHAGIA; FEMALE; FISHER EXACT TEST; HAND DISEASE; HLA TYPING; HUMAN; IDIOPATHIC DISEASE; IMMUNOGENETICS; IMMUNOPRECIPITATION; INTERSTITIAL LUNG DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYOSITIS; POLYMERASE CHAIN REACTION; PREVALENCE; PROPORTIONAL HAZARDS MODEL; SJOEGREN SYNDROME; STATISTICAL SIGNIFICANCE; STUDENT T TEST; SURVIVAL; SURVIVAL RATE;

EID: 33750369824     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.22237     Document Type: Article

References (45)

1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
2. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991;325:1487-98.
3. Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest 2001;108:1417-22.
4. Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 2000;12:475-81.
5. Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002;28:859-90.
6. Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990; 77:1019-38.
7. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990;33:1361-70.
8. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 1985;28:796-803.
9. Nilasena DS, Trieu EP, Targoff IN. Analysis of the Mi-2 autoantigen of dermatomyositis. Arthritis Rheum 1995;38:123-8.
10. Seelig HP, Moosbrugger I, Ehrfeld H, Fink T, Renz M, Genth E. The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum 1995;38:1389-99.
11. Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998;95:279-89.
12. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
13. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
14. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74.
15. Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW, and the International Myositis Collaborative Study Group. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003;48:2285-93.
16. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, Jarzabek-Chorzelska M, Targoff IN, Blaszczyk-Kostanecka M, et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:1257-66.
17. Hengstman GJ, van Engelen BG, Vree Egberts WT, van Venrooij WJ. Myositis-specific autoantibodies: overview and recent developments. Curr Opin Rheumatol 2001;13:476-82.
18. Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-23.
19. Hengstman GJ, Brouwer R, Egberts WT, Seelig HP, Jongen PJ, van Venrooij WJ, et al. Clinical and serological characteristics of 125 Dutch myositis patients: myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002;249:69-75.
20. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-13.
21. Hirakata M, Suwa A, Nagai S, Kron MA, Trieu EP, Mimori T, et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999;162:2315-20.
22. Selva-O'Callaghan A, Mijares-Boeckh-Behrens T, Labrador-Horrillo M, Solans-Laque R, Ma Grau-Junyent J, Vilardell-Tarres M. Anti-PM-Scl antibodies in a patient with inclusion body myositis. Rheumatology (Oxford) 2003;42:1016-8.
23. Pardos Gea J, Selva-O'Callaghan A, Sans Valeta J, Grau Junyent JM. Inclusion body myositis and primary Sjögren syndrome [letter]. Med Clin (Barc) 2003;120:318-9. In Spanish.
24. Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA Jr. Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic associations. Arthritis Rheum 1992;35:1211-7.
25. Brouwer R, Pruijn GJ, van Venrooij WJ. The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma. Arthritis Res 2001;3:102-6.
26. Brouwer R, Vree Egberts WT, Hengstman GJ, Raijmakers R, van Engelen BG, Seelig HP, et al. Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res 2002;4:134-8.
27. Raijmakers R, Renz M, Wiemann C, Vree Egberts W, Seelig HP, van Venrooij WJ, et al. PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome. Arthritis Rheum 2004;50:565-9.
28. Pope JE. Scleroderma overlap syndromes. Curr Opin Rheumatol 2002;14:704-10.
29. Marguerie C, Bunn CC, Copier J, Bernstein RM, Gilroy JM, Black CM, et al. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992;71:327-36.
30. Mimori T, Hinterherger M, Pettersson I, Steitz JA. Autoantibodies to the U2 small nuclear ribonucleoprotein in a patient with scleroderma-polymyositis overlap syndrome. J Biol Chem 1984;259:560-5.
31. Coppo P, Clauvel IP, Bengoufa D, Oksenhendler E, Lacroix C, Lassoued K. Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome. Rheumatology (Oxford) 2002;41:1040-6.
32. Kubo M, Ihn H, Kuwana M, Asano Y, Tamaki T, Yamane K, et al. Anti-U5 snRNP antibody as a possible serological marker for scleroderma-polymyositis overlap. Rheumatology (Oxford) 2002;41:531-4.
33. Franceschini F, Cavazzana I, Generali D, Quinzanini M, Viardi L, Ghirardello A, et al. Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. J Rheumatol 2002;29:1393-7.
34. Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Homma M. Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum 1992;35:449-56.
35. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002;73:420-8.
36. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004;50:209-15.
37. Schmidt WA, Wetzel W, Friedlander R, Lange R, Sorensen HF, Lichey HJ, et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies: an evolving spectrum of disease manifestations. Clin Rheumatol 2000;19:371-7.
38. Uthman I, Vazquez-Abad D, Senecal JL. Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum 1996;26:447-58.
39. Goldstein R, Duvic M, Targoff IN, Reichlin M, McMenemy AM. Reveille JD, et al. HLA-D region genes associated with autoantibody responses to histidyl-transfer RNA synthetase (Jo-1) and other translation-related factors in myositis. Arthritis Rheum 1990;33:1240-8.
40. Hengstman GJ, van Engelen BG, van Venrooij WJ. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatology 2004;16:692-9.
41. Levine SM, Rosen A, Casciola-Rosen LA. Anti-aminoacyl tRNA synthetase immune responses: insights into the pathogenesis of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2003;15:708-13.
42. Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002;196:781-91.
43. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996;26:459-67.
44. Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun 1999;12:137-42.
45. Rutjes SA, Vree Egberts WT, Jongen P, van den Hoogen F, Pruijn GJ, van Venrooij WJ. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997;109:32-40.